Short Term Rating on Mallinckrodt plc (MNK)

Mallinckrodt plc (MNK) : 12 analysts are covering Mallinckrodt plc (MNK) and their average rating on the stock is 1.21, which is read as a Strong Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Mallinckrodt plc (MNK) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Mallinckrodt plc (MNK) : Currently there are 11 street experts covering Mallinckrodt plc (MNK) stock. The most bullish and bearish price target for the stock is $115 and $75 respectively for the short term. The average price target of all the analysts comes to $90. The estimated standard deviation from the target is $11.74.

For the current week, the company shares have a recommendation consensus of Buy.


Mallinckrodt plc (NYSE:MNK): The stock opened at $62.46 on Tuesday but the bulls could not build on the opening and the stock topped out at $62.56 for the day. The stock traded down to $61.53 during the day, due to lack of any buying support eventually closed down at $61.90 with a loss of -0.99% for the day. The stock had closed at $62.52 on the previous day. The total traded volume was 1,962,645 shares.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.